Multifunctional organic–inorganic hybrid nanoparticles and nanosheets based on chitosan derivative and layered double hydroxide: cellular uptake mechanism and application for topical ocular drug delivery

Male Medicine (General) Administration, Ophthalmic 02 engineering and technology Cell Line Cornea R5-920 Drug Delivery Systems International Journal of Nanomedicine Oxazines Hydroxides Animals Humans Human corneal epithelial primary cell (HCEpic) Organic Chemicals Original Research Ocular drug delivery Chitosan Cell Death Active targeting Epithelial Cells Flow Cytometry Endocytosis 3. Good health Drug Liberation Microscopy, Fluorescence Retinal pigment cell (ARPE-19) Inorganic Chemicals LDH nanoparticles Nanoparticles Ophthalmic Solutions 0210 nano-technology LDH nanosheets
DOI: 10.2147/ijn.s129311 Publication Date: 2017-02-28T21:52:06Z
ABSTRACT
To study the cellular uptake mechanism of multifunctional organic-inorganic hybrid nanoparticles and nanosheets, new chitosan-glutathione-valine-valine-layered double hydroxide (CG-VV-LDH) nanosheets with active targeting to peptide transporter-1 (PepT-1) were prepared, characterized and further compared with CG-VV-LDH nanoparticles. Both organic-inorganic hybrid nanoparticles and nanosheets showed a sustained release in vitro and prolonged precorneal retention time in vivo, but CG-VV-LDH nanoparticles showed superior permeability in the isolated cornea of rabbits than CG-VV-LDH nanosheets. Furthermore, results of cellular uptake on human corneal epithelial primary cells (HCEpiC) and retinal pigment epithelial (ARPE-19) cells indicated that both clathrin-mediated endocytosis and active transport of PepT-1 are involved in the internalization of CG-VV-LDH nanoparticles and CG-VV-LDH nanosheets. In summary, the CG-VV-LDH nanoparticle may be a promising carrier as a topical ocular drug delivery system for the treatment of ocular diseases of mid-posterior segments, while the CG-VV-LDH nanosheet may be suitable for the treatment of ocular surface diseases.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (39)